Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Podrobná bibliografie
Hlavní autoři:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Médium:	Journal article
Jazyk:	English
Vydáno:	MDPI 2021

Podobné jednotky

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
Autor: Michael Riste, a další
Vydáno: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
Autor: Thomas, Z, a další
Vydáno: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Autor: Tameris, M, a další
Vydáno: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
Autor: Tameris, M, a další
Vydáno: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Autor: Mcshane, H
Vydáno: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
Autor: Manjaly Thomas, Z, a další
Vydáno: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Autor: Rowland, R, a další
Vydáno: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Autor: Michele Tameris, a další
Vydáno: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
Autor: Harris, S, a další
Vydáno: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Autor: Meyer, J, a další
Vydáno: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Autor: Meyer, J, a další
Vydáno: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Autor: Zita-Rose Manjaly Thomas, a další
Vydáno: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Autor: Anne Wajja, a další
Vydáno: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Autor: Wajja, A, a další
Vydáno: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
Autor: Sander, C, a další
Vydáno: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
Autor: Minassian, A, a další
Vydáno: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
Autor: Harris, S, a další
Vydáno: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Autor: Odutola, A, a další
Vydáno: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Autor: Odutola, A, a další
Vydáno: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
Autor: Dieye, T, a další
Vydáno: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
Autor: Wilkie, M, a další
Vydáno: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Autor: Whelan, K, a další
Vydáno: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Autor: Pathan, A, a další
Vydáno: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Autor: Pathan, A, a další
Vydáno: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Autor: Owiafe, P, a další
Vydáno: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
Autor: Tandakha N Dieye, a další
Vydáno: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Autor: Kathryn T. Whelan, a další
Vydáno: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
Autor: Wilkie, M, a další
Vydáno: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
Autor: Tandakha N. Dieye, a další
Vydáno: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Autor: Minhinnick, A, a další
Vydáno: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
Autor: C.N. Govind, a další
Vydáno: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
Autor: F. Ismail, a další
Vydáno: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Vydáno: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
Autor: Raksha Rimal, a další
Vydáno: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
Autor: Giovana Rodrigues Pereira, a další
Vydáno: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
Autor: Neeraj Raizada, a další
Vydáno: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
Autor: Mcshane, H, a další
Vydáno: (2016)

TB or not TB?
Autor: Andrew Pirotte, a další
Vydáno: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Autor: Satti, I, a další
Vydáno: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
Autor: Satti, I, a další
Vydáno: (2014)